Marinus Pharmaceuticals to Present at the 2023 Cantor Global Healthcare Conference
2023年9月22日 - 5:00AM
ビジネスワイヤ(英語)
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical
company dedicated to the development of innovative therapeutics to
treat seizure disorders, today announced that Scott Braunstein,
M.D., Chairman and Chief Executive Officer, will be participating
in a fireside chat at the 2023 Cantor Global Healthcare
Conference.
The fireside chat will take place on Thursday, September 28
beginning at 10:55 a.m. Eastern Time.
A link to the event can be accessed on the Investors and Media
page of Marinus’ website at
ir.marinuspharma.com/events-and-presentations. A replay of the
webcast will be available approximately two hours after the
completion of the event and will be archived for up to 90 days.
About Marinus Pharmaceuticals
Marinus is a commercial-stage pharmaceutical company dedicated
to the development of innovative therapeutics for seizure
disorders. The Company first introduced FDA-approved prescription
medication ZTALMY® (ganaxolone) oral suspension CV in the U.S. in
2022 and continues to invest in the potential of ganaxolone in IV
and oral formulations to maximize therapeutic reach for adult and
pediatric patients in acute and chronic care settings. For more
information about Marinus visit www.marinuspharma.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230921535766/en/
Investors Jim DeNike Senior
Director, Investor Relations Marinus Pharmaceuticals, Inc.
jdenike@marinuspharma.com
Media Molly Cameron
Director, Corporate Communications & Investor Relations Marinus
Pharmaceuticals, Inc. mcameron@marinuspharma.com
Marinus Pharmaceuticals (NASDAQ:MRNS)
過去 株価チャート
から 4 2024 まで 5 2024
Marinus Pharmaceuticals (NASDAQ:MRNS)
過去 株価チャート
から 5 2023 まで 5 2024